

***Plasmodium falciparum* Erythrocyte Binding Antigen-175 RII-Non-Glycosylated Protein, Recombinant from *Pichia pastoris***

**Catalog No. MRA-1162**

This reagent is the tangible property of the U.S. Government.

**For research use only. Not for human use.**

**Contributor and Manufacturer:**

Annie Mo, Ph.D., Program Officer, Preclinical Vaccine Development, Parasitology and International Programs Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

**Product Description:**

Recombinant *Plasmodium falciparum* erythrocyte binding antigen (EBA)-175 RII-non-glycosylated (NG) protein was expressed as a secreted protein and purified from *Pichia pastoris*, strain X33.

EBA-175 protein is a malaria vaccine candidate and a parasite ligand at the apical end of the *Plasmodium falciparum* merozoite that binds sialic acids of glycophorin A on the surface of erythrocytes. EBA-175 RII-NG contains the 616 amino acid Region II (RII) with conservative NG mutations.<sup>1</sup>

**Material Provided:**

Each vial contains approximately 500 µg of purified recombinant EBA-175 RII-NG in 6 mM sodium phosphate, 154 mM sodium chloride and 5% w/v sucrose (pH 7.2). Sucrose should be included in storage buffer to prevent dimer formation.<sup>2</sup> The concentration, expressed as mg per mL, is shown on the Certificate of Analysis.

**Packaging/Storage:**

MRA-1162 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -80°C or colder immediately upon arrival.

**Citation:**

Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: *Plasmodium falciparum* Erythrocyte Binding Antigen-175 RII-Non-Glycosylated Protein, Recombinant from *Pichia pastoris*, MRA-1162, contributed by Annie Mo.”

**Biosafety Level: 1**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories](#). 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see [www.cdc.gov/biosafety/publications/bmbl5/index.htm](http://www.cdc.gov/biosafety/publications/bmbl5/index.htm).

**Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:**

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

**References:**

1. Mo, A., Personal Communication.
2. Peek, L. J., et al. “A Systematic Approach to Stabilizing EBA-175 RII-NG for Use as a Malaria Vaccine.” [Vaccine](#) 24 (2006): 5839-5851. PubMed: 16735084.

ATCC® is a trademark of the American Type Culture Collection.

